APLS (Apellis Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by APLS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Caroline Baumal | Chief Medical Officer | MIXED | — | — |
| 2026-05-14 | Cedric Francois | Chief Executive Officer | MIXED | — | — |
| 2026-05-14 | David O. Watson | General Counsel | MIXED | — | — |
| 2026-05-14 | CRAIG A WHEELER | Director | MIXED | — | — |
| 2026-05-14 | Kelley Boucher | Chief People Officer | MIXED | — | — |
| 2026-05-14 | Stephanie Monaghan O'Brien | Director | MIXED | — | — |
| 2026-05-14 | Mark Jeffrey DeLong | Chief Business & Strat Officer | MIXED | — | — |
| 2026-05-14 | Keli Walbert | Director | MIXED | — | — |
| 2026-05-14 | Nur Nicholson | Chief Technical Officer | MIXED | — | — |
| 2026-05-14 | Gerald Chan | Director | MIXED | — | — |
| 2026-05-14 | Pascal Deschatelets | Chief Scientific Officer | MIXED | — | — |
| 2026-05-14 | Alec Machiels | Director | MIXED | — | — |
| 2026-05-14 | Timothy Eugene Sullivan | Chief Financial Officer | MIXED | — | — |
| 2026-05-14 | PAUL R. FONTEYNE | Director | MIXED | — | — |
| 2026-05-14 | LESLIE MELTZER | Chief Research and Development | MIXED | — | — |
| 2026-05-14 | Mikael Dolsten | Director | MIXED | — | — |
| 2026-05-14 | James George Chopas | VP/Chief Accounting Officer | MIXED | — | — |
| 2026-05-14 | A. Sinclair Dunlop | Director | MIXED | — | — |
| 2026-05-01 | Caroline Baumal | Chief Medical Officer | G | — | — |
| 2026-04-20 | Timothy Eugene Sullivan | Chief Financial Officer | G | — | — |
| 2026-04-08 | Stephanie Monaghan O'Brien | Director | J | — | — |
| 2026-03-13 | Cedric Francois | Chief Executive Officer | G | — | — |
| 2026-03-03 | Mikael Dolsten | Director | A | — | — |
| 2026-02-13 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | — | — |
| 2026-02-05 | Cedric Francois | Chief Executive Officer | M | — | — |
| 2026-01-30 | Cedric Francois | Chief Executive Officer | A | — | — |
| 2026-01-30 | David O. Watson | General Counsel | A | — | — |
| 2026-01-30 | Timothy Eugene Sullivan | Chief Financial Officer | A | — | — |
| 2026-01-30 | Nur Nicholson | Chief Technical Officer | A | — | — |
| 2026-01-30 | LESLIE MELTZER | Chief Research and Development | A | — | — |
| 2026-01-30 | Pascal Deschatelets | Chief Scientific Officer | A | — | — |
| 2026-01-30 | Mark Jeffrey DeLong | Chief Business & Strat Officer | A | — | — |
| 2026-01-30 | James George Chopas | VP/Chief Accounting Officer | A | — | — |
| 2026-01-30 | Kelley Boucher | Chief People Officer | A | — | — |
| 2026-01-23 | David O. Watson | General Counsel | Sell | — | — |
| 2026-01-23 | Timothy Eugene Sullivan | Chief Financial Officer | Sell | — | — |
| 2026-01-23 | Nur Nicholson | Chief Technical Officer | Sell | — | — |
| 2026-01-23 | Cedric Francois | Chief Executive Officer | Sell | — | — |
| 2026-01-23 | Pascal Deschatelets | Chief Scientific Officer | Sell | — | — |
| 2026-01-23 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | — | — |
| 2026-01-23 | James George Chopas | VP/Chief Accounting Officer | Sell | — | — |
| 2026-01-23 | Caroline Baumal | Chief Medical Officer | Sell | — | — |
| 2026-01-21 | David O. Watson | General Counsel | Sell | — | — |
| 2026-01-21 | Timothy Eugene Sullivan | Chief Financial Officer | Sell | — | — |
| 2026-01-21 | Nur Nicholson | Chief Technical Officer | Sell | — | — |
| 2026-01-21 | Cedric Francois | Chief Executive Officer | Sell | — | — |
| 2026-01-21 | Pascal Deschatelets | Chief Scientific Officer | Sell | — | — |
| 2026-01-21 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | — | — |
| 2026-01-21 | James George Chopas | VP/Chief Accounting Officer | Sell | — | — |
| 2026-01-21 | Caroline Baumal | Chief Medical Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 12,806,342 | — |
| — | 10%+ Owner | 3,451,790 | — |
| — | 10%+ Owner | 2,402,497 | — |
| — | 10%+ Owner | 2,292,062 | — |
| — | 10%+ Owner | 2,098,581 | — |
| — | 10%+ Owner | 943,989 | — |
| — | Chief Executive Officer | 195,952 | — |
| — | Chief Medical Officer | 94,884 | — |
| — | Chief Commercial Officer | 84,050 | — |
| — | Chief Research Officer | 78,299 | — |
| — | Chief People Officer | 70,251 | — |
| — | Chief Development Officer | 55,312 | — |
| — | Chief Business Officer | 50,110 | — |
| — | Chief Technical Officer | 24,284 | — |
| — | Program Team Lead | 23,556 | — |
| — | VP/Chief Accounting Officer | 8,075 | — |
| — | See Remarks | 7,725 | — |
| — | Vice President - Accounting | 5,847 | — |
| — | See Remarks | 5,213 | — |
| — | See Remarks | 2,725 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APLS quote page; the site-wide leaderboard is on the insider transactions hub.